Evidence map›Paper›PMID 41250049›Full record

ArticleJournal of translational medicine2025

Placenta-derived trophoblast extracellular vesicles promote CD169

Xinyi Sun, Lawrence W Chamley, Terry Morgan, Sofian Tijono, Bridget Tsai, Leana Terblanche, Lai-Ming Ching, Qi Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinyi SunDepartment of Obstetrics, Gynaecology and Reproductive Sciences, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand.
Lawrence W ChamleyDepartment of Obstetrics, Gynaecology and Reproductive Sciences, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand.
Terry MorganDepartment of Pathology and Laboratory Medicine, School of Medicine, Oregon Health & Science University, Portland, Maine, USA.
Sofian TijonoAuckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand.
Bridget TsaiDepartment of Obstetrics, Gynaecology and Reproductive Sciences, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand.
Leana TerblancheDepartment of Obstetrics, Gynaecology and Reproductive Sciences, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand.
Lai-Ming ChingAuckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand.
Qi ChenDepartment of Obstetrics, Gynaecology and Reproductive Sciences, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand. q.chen@auckland.ac.nz.ORCID 0000-0001-5894-6331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA lower survival rate due to a later stage of diagnosis requires a more effective therapy for ovarian cancer. Extracellular vesicles (EVs) have shown therapeutic potential in various diseases, partly due to their ability to modulate immune responses. We previously showed that placental-derived trophoblast EVs suppressed ovarian tumour growth, accompanied by increased infiltration of CD169

methodSKOV-3 ovarian cancer cell xenografts were intraperitoneally injected with placental-derived trophoblast EVs. Tumour growth was monitored, and EV biodistribution was tracked at four time points. Additionally, the dynamics of CD169

resultsA reduction of tumour growth after EV treatment was observed. At early time points (within 24 hours), trophoblast EVs preferentially accumulated in immune organs, including the inguinal lymph nodes, but not in tumours. The significantly higher intensity of CD169

conclusionPlacental-derived trophoblast EVs may act as an immune modulator, specifically in the presence of tumours, through promoting CD169

Indexed as

Cell MovementExtracellular VesiclesMacrophagesOvarian NeoplasmsPlacentaSialic Acid Binding Ig-like Lectin 1TrophoblastsAnimalsCell Line, TumorCell ProliferationFemaleHumansKiller Cells, NaturalMicePregnancySialic Acid Binding Ig-like Lectin 1CD169Extracellular vesicleOvarian cancerPlacentaTumour xenograft model

Identifiers

PMID41250049
PMCPMC12625331

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.